Chronic inflammation contributes to a broad spectrum of diseases including arthritis, psoriasis, diabetes, allergy, connective tissue diseases, and heart disease. Despite the range of current therapeutics on offer, there is unmet clinical need as treatments such as corticosteroids, though often effective, are associated with serious side effects.
Based upon the selective properties of ES-62, a parasitic immunomodulatory molecule derived from a parasitic nematode, scientists at Strathclyde have produced a series of small molecule derivatives that are able to suppress inflammatory responses both in vitro and in vivo but only when aberrant hyper-inflammatory responses have been invoked. Thus, these compounds have the potential to provide a range of highly selective and safe drugs that do not immunocompromise the patient.
This project seeks to optimise the structures of new compounds based upon the properties of ES-62, leading to clinical candidates for the treatment of asthma and rheumatoid arthritis.
· New class of anti-inflammatory agents with good drug gability and easy synthetic access
· Novel biological mechanism of action based upon the properties of the immunomodulatory protein, ES-62
· Broad portfolio of potential target diseases
· Selective immunomodulation as the patient remains 'immune-competent' and able to fight off infections
Markets and Applications
This technology has the potential to treat many inflammatory-based conditions such as rheumatoid arthritis, systemic lupus erythematosus and asthma. 60.4 million people across the seven major markets suffered with asthma in 2010 with 16.5% of Britons being affected.
Contact is welcomed from organisations interested in developing, licensing or exploiting this technology.